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The coagulation system links immediate (hemostatic) and late
(inflammatory, angiogenic) tissue responses to injury, a continuum
that often is subverted in cancer. Here we provide evidence that
tumor dormancy is influenced by tissue factor (TF), the cancer cell-
associated initiator of the coagulation system and a signaling
receptor. Thus, indolent human glioma cells deficient for TF remain
viable but permanently dormant at the injection site for nearly
a year, whereas the expression of TF leads to a step-wise tran-
sition to latent and overt tumor growth phases, a process that is
preceded by recruitment of vascular (CD105+) and myeloid (CD11b+
and F4/80+) cells. Importantly, the microenvironment orchestrated
by TF expression drives permanent changes in the phenotype, gene-
expression profile, DNA copy number, and DNA methylation state
of the tumor cells that escape from dormancy. We postulate that
procoagulant events in the tissue microenvironment (niche) may
affect the fate of occult tumor cells, including their biological and
genetic progression to initiate a full-blown malignancy.
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The interplay between intrinsic (oncogenic) and external(microenvironmental) influences defines many aspects of the
natural history of human cancers, including the process of tumor
dormancy (1). This aspect is important because it remains un-
clear what controls the dormant state of solitary transformed
cells that are detectable in various organs with prevalence
that often far exceeds the site-specific incidence of the cor-
responding cancers (2–9).
Dormancy may entail a stable equilibrium between cell growth
and death within the microscopic tumor nodule (3, 10, 11),
a state which should be distinguished from slow, subclinical, but
otherwise progressive (latent) disease (12). In addition to cell-
intrinsic growth mechanisms, the dormant state also may be
controlled by immune surveillance (13), interactions with bone
marrow-derived inflammatory cells (14), or the angiogenic ac-
tivity of the vasculature (3).
The coagulation system rarely is considered in this context,
even though it constitutes the key element of the continuum of
hemostasis, inflammation, angiogenesis, and tissue responses to
injury (15–17). Activation of the coagulation system is relatively
common in late-stage cancers (18), but emerging data suggest
that cancer incidence also may increase in certain (but not all)
thrombophilic syndromes (19) and may be affected by regulators
of the coagulation system (20).
Tissue factor (TF) is the key inducer of the coagulation cas-
cade and functions as the receptor for coagulation factor VII/
VIIa, a zymogen that normally circulates in blood. The forma-
tion of TF/VIIa complexes on cellular surfaces triggers the
generation of active coagulation proteases (especially factor Xa
and thrombin), followed by deposition of activated platelets and
fibrin. Protracted or unscheduled onset of these events in cancer
may result in vascular occlusion and hypoxia, and in signals that
influence inflammation, angiogenesis, and other cellular responses
(21). These events are attributed, in part, to the ability of clotting
factors (VIIa, Xa, thrombin) to induce changes in the gene-
expression profile (22), largely through the activation of the
protease-activated receptors PAR-1 and -2, integrins, and other
TF pathway effectors (17).
The coagulation system has a special role in the pathogenesis
of glioblastoma multiforme (GBM) (23), in which hypervascularity
and thromboembolic vascular occlusions result in pseudopalisad-
ing necrosis, which is characteristic of this aggressive brain tumor
(21). Moreover, GBM is associated with systemic deregulation of
hemostasis (21, 24) and with the increased expression of TF (25)
resulting from a combination of hypoxia (26) and genetic aber-
rations, including oncogenic mutations of EGF receptor (EGFR)/
EGFRvIII (27–31). Although the temporal relevance of these
events is presently unknown, studies have linked the incidence of
GBM with head injury (32, 33), for reasons that remain poorly
understood and are scarcely studied.
Here we show that TF expression may impact early stages of
gliomagenesis by influencing the dormancy of transformed but
indolent tumor cells. Thus, U373 glioma cells that express low
levels of TF remain viable but permanently nontumorigenic in
mice, and this dormant state can be disrupted by exogenous
expression of TF. These events are preceded by the formation of
a microenvironment containing angiogenic and inflammatory
cells, triggering genetic tumor progression manifested by changes
in gene copy number and DNA methylation.
Significance
Our study shows that the clotting protein tissue factor (TF)
controls the state of tumor dormancy and does so in conjunc-
tion with recruitment of inflammatory cells and blood vessels.
We show that indolent glioma cells remain harmless in mice
unless rendered TF positive. Our work also demonstrates the
ability of TF to indirectly influence the DNA of cancer cells by
facilitating gene mutations and silencing. This ability is im-
portant because injury, cardiovascular disease, or other con-
ditions may activate the clotting system and contribute to the
awakening of occult cancer cells. This understanding also may
suggest a prophylactic use of blood thinners in cases where
dormant cancer cells and clotting are suspected to coexist (e.g.,
after surgery).
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Results
TF-Deficient Glioma Cells Exhibit Dormant Phenotype. The fate of
glioma cells before the onset of clinically apparent lesions is
presently unknown, especially in the case of primary GBM
(without the preceding low-grade disease) (23). To explore this
process experimentally, we used an indolent subline of U373
cells that is completely nontumorigenic, as documented by sev-
eral rounds of s.c. or intracranial injection of large numbers of
cancer cells that yielded no growth even after extended obser-
vation time (31).
Interestingly, using Luciferase-tagged U373 cells (EV-U373),
we observed that these cells are not eliminated upon inoculation
into immune-deficient mice. Rather, they remain present per-
manently (i.e., for more than 1 y) at the injection site, viable and
metabolically active, but without evidence of palpable tumor
growth. In contrast, the EGFRvIII-expressing counterparts of
these cells (U373vIII) form aggressive tumors in 100% of mice,
reaching the clinical end point within 50–70 d (Fig. 1 A, C, and
D). This pattern was observed regardless of whether glioma cells
were inoculated s.c. or orthotopically (intracranially). Moreover,
such differences could not be inferred from in vitro properties of
these respective cell lines, both of which grow readily in culture,
albeit at somewhat different rates (SI Appendix, Fig. S1 A and B).
Indeed, the in vivo behavior of EV-U373 cells is one of the most
striking examples of stable tumor dormancy described in the
literature (3).
Expression of TF Is Sufficient to Interrupt Tumor Cell Dormancy. The
contrasting biological properties of EV-U373 and U373vIII cells
in vivo are paralleled by dramatic differences in their TF ex-
pression. Thus, U373 (or EV-U373) cells are largely TF negative,
but their U373vIII derivatives express large amounts of TF
protein and procoagulant activity, as described previously (27,
30). To assess whether the absence of TF activity contributes to
the dormant phenotype, U373 cells were engineered to express
full-length human TF, and several independent clones were
characterized for procoagulant and tumorigenic properties (Fig.
1 and SI Appendix, Table S1 and Fig. S3A). Notably, all empty-
vector transfectants (EV-U373) and TF-low expressors (TF-
U373–low) retained their permanently dormant characteristics.
However, TF-U373 cells expressing higher TF levels, compara-
ble to those achievable endogenously in the presence of the
EGFRvIII oncogene, exited the dormant state readily.
Of note, TF-expressing cells did not exhibit palpable tumors
until 60–70 d postinjection; only after this latent period did they
begin to form overt lesions rapidly (SI Appendix, Table S1).
These characteristics were retained even when tumor cells were
coinjected with Matrigel, which often facilitates experimental
tumor formation. In this setting the TF-deficient parental pop-
ulation remained permanently dormant, but TF-expressing clones
exhibited a somewhat increased tumor take rate and shortened
time to progression. In all cases, after the initial tumor onset, full-
blown disease developed within 5–6 mo postinjection and rapidly
reached the clinical end point (Fig. 1 A, C, and D).
It is noteworthy that in only one of many series of such cell
injections, one of 14 mice inoculated s.c. with the same prepa-
ration of control U373 cells developed an overt tumor (SI Ap-
pendix) after several weeks of latency. In this case the cell line
reestablished in culture from the tumor mass (PT-EV-U373)
exhibited high and stable levels of TF expression. A similar
spontaneous increase in TF expression also had been observed
earlier in several tumorigenic variants generated by in vivo pas-
sage of their indolent predecessors originating from colorectal
cancer (Hhk-2), or melanoma (WM35; WM1341b) (SI Appen-
dix). Thus in many cases the onset of TF expression is linked
closely (causally) to a loss of indolent phenotype in vivo.
TF Provokes Early Recruitment of Blood Vessels and Myeloid Cells to
Sites of Latent Tumor Growth.Despite strikingly different behavior
in vivo, TF-expressing U373 glioma sublines are indistinguish-
able from their control counterparts with respect to morphology
and in vitro growth potential (SI Appendix). This similarity sug-
gests that their differences are the result of interactions with the
host cell compartment. In this regard, we were especially puzzled
by the ability of TF to trigger tumor formation, not immediately
but only after a relatively lengthy latency.
To capture the events occurring between the time of cancer
cell inoculation and the onset of tumor growth, we chose to inject
observable numbers of tumor cells embedded within s.c. Matrigel
pellets. Unlike small cranial inocula, which often are difficult to
locate, Matrigel pellets are readily extracted and analyzed his-
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Fig. 1. TF expression drives the escape of tumors from dormancy. (A) Dor-
mant phenotype of EV-U373 cells is interrupted by the expression of TF.
(Left) Bioluminescent imaging of Luciferase-expressing cell lines upon
orthotopic injection into SCID mice. TF-U373-G11 cells injected intracranially
remain latent but eventually emerge as detectable tumors. (Right) Quanti-
tative plots of all tumors included in these experiments. (B) Flow cytometry
shows immunostaining for the cell-surface expression of TF in parental/
control cells (EV-U373), their derivatives expressing EGFRvIII (U373vIII), and
an example of the TF transfectant clone (TF-U373-G11); compare with data
in SI Appendix, Table S1. (C) Dormant phenotype of EV-U373 cells inoculated
s.c. is interrupted by the enforced expression of TF. (Left) Bioluminescent
images of s.c. tumors that were generated by EV-373, TF-U373-G11, and
U373vIII cells. (Right) Cumulative growth plots combining all mice in the
respective groups. (D) Impact of TF expression on survival of mice harboring
dormant and aggressive glioma xenografts. Representative Kaplan–Meier
plots depict survival of mice; n = 5 per group. EV-U373 cells remain dormant;
TF-U373-G11 and TF-U373-D11 cell lines engineered to express TF form
tumors after a long latency and with less than 100% tumor take rate (SI
Appendix). PT, primary tumor cells derived by culturing cells isolated from
TF-U373 tumors. Significance of differences was assessed by log-rank test;
***P < 0.0005.











chose to exploit these properties to observe the dormant be-
havior of U373 (EV-U373) cells and the latency of their TF-
U373 counterparts (Fig. 2A and SI Appendix).
Using this approach, we noted that distinct cellular patterns be-
gan to emerge within the first 2–3 wk postinjection, that is, several
weeks before the observable tumor onset. In this regard, day 16
postinoculation was chosen for consistency (Fig. 2B) and used
to assess TF-dependent events such as rates of tumor cell pro-
liferation (Ki67) and apoptosis (TUNEL), both of which were
unremarkable.
In contrast, striking differences were observed in host cell
recruitment. By day 16 after injection (1–2 mo before tumor
onset), the TF-U373-containing Matrigel pellets became in-
tensely vascularized with CD105+ capillary structures. This in-
filtration reached a median of 44.5 vessels per pellet (n = 6) as
enumerated at high-power (40×) magnification, with at least 10
fields per pellet counted. At the same time postinoculation
a median of only 7.3 vessels was observed in pellets containing
control EV-U373 cells (P < 0.05; Fig. 2C, Top).
Moreover, pellets containing TF-U373 cells, unlike controls,
were visibly infiltrated with CD45+ leukocytes, a difference that
could be visualized by immunofluorescence and quantified by
flow cytometry upon enzymatic dispersion of Matrigel and re-
covery of embedded cells (Fig. 2C, Middle). Interestingly, an
even greater difference was observed in the content of cells with
characteristics of CD11b+ myeloid bone marrow derived cells
(BMDCs) (34) and F4/80+ macrophages (Fig. 2C, Bottom). Col-
lectively, these observations suggest that the expression of TF in
indolent U373 glioma results in transition from dormancy to la-
tency, which is preceded (by 3–4 wk or more) by macrophage/
myeloid infiltration and the onset of angiogenesis.
Molecular Responses of Glioma Cells to the TF-Modulated Micro-
environment. We reasoned that changes in gene expression would
be expected to precede the profound biological transition ac-
companying the onset of tumor growth by TF-U373 cells. To
address this question, Matrigel pellets containing TF-U373 (clone
G11) cells or their isogenic EV-373 counterparts were extracted
from several mice at 16 d after inoculation, and the expression of
human transcripts was analyzed using the Affymetrix Human
Genome Array U133 plus 2.0 platform (SI Appendix, Fig. S2).
Indeed, we observed that multiple human genes were expressed
differently in the inocula of TF-expressing and -nonexpressing
cells. Of those genes, 319 were up-regulated at least twofold in
TF-U373 cells relative to their EV-U373 controls, and 365 genes
were down-regulated by at least twofold. The list in SI Appendix,
Fig. S2A shows the most dramatic differences (the top 10 over-
expressed and top 10 down-regulated genes), several of which
were validated by RT-PCR (SI Appendix, Fig. S2B). Perhaps not
surprisingly, these genes are reflective of developmental (KLHL4,
SOX11), mitogenic (MYCN), or biosynthetic (RPS4Y1) functions,
and their general pattern places the changes mostly within Cellular
Movement, Cancer and Cellular Development regulatory path-
ways [Ingenuity Pathways Analysis (IPA)] (SI Appendix). Inter-
estingly the connectivity mapping of molecular changes imparted by
TF expression during tumor latency points to similarities with in-
flammatory and cell movement pathways, mostly converging on the
respective cytokine networks (SI Appendix). This result is not un-
anticipated, because the procoagulant microenvironment is linked
in several complex ways to pathways of inflammation (35). Thus,
the expression of TF by tumor cells may cause changes in their
pericellular microenvironment, which in turn could provoke a re-
ciprocal alteration in cellular transcriptome.
TF-Imposed Exit from Dormancy Is Associated with Permanent
Alterations in Tumor Cell Phenotype, Genome, and Epigenome. It is
reasonable to ask whether passage through the latency period
and the subsequent onset of aggressive growth in vivo, as hap-
pens with TF-U373 cells, can be recapitulated upon their rein-
jection into secondary recipients (Fig. 1D). To investigate this
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Fig. 2. Angiogenesis and inflammation precede TF-driven tumor escape
from dormancy. (A) Diagram showing the analysis of molecular and cellular
changes preceding the escape from tumor dormancy. Tumor cells embedded
in Matrigel were injected on day 0, and the pellets were retrieved on day 16.
The cellular content of pellets was analyzed for cellular and molecular
parameters as indicated (see text). (B) Staining of tumor inoculates for
markers of proliferation (KI67) and apoptosis (TUNEL). EV-U373 and TF-
U373-G11 pellets contain comparable numbers of dividing and apoptotic
cells. (Upper) Quantification of KI67 at 40× magnification; n = 4; P > 0.05.
(Lower) TUNEL staining; n = 4; P > 0.05. (C) Changes in the content of en-
dothelial and leukocytic cells as a function of TF expression by glioma cells.
(Top Row) Immunohistochemistry for CD105 reveals a differential influx of
endothelial cells and blood vessels into Matrigel pellets containing EV-U373
and TF-U373-G11 cells. (Right) Quantification of CD105-positive vascular
structures, n = 6; *P < 0.05. (Second Row) (Left) Immunohistochemistry for
CD45+ cells (arrows). (Right) Flow cytometry quantification of CD45+ leu-
kocytic cells within Matrigel pellets. n = 3; *P < 0.05. (Third Row) (Left)
Immunostaining for CD11b+ myeloid cells in tumor cell-containing Matrigel
pellets (black arrows). (Right) Flow cytometry quantification of CD11b+ cells
in Matrigel pellets. n = 3; *P < 0.05. (Bottom Row) (Left) Immunostaining for
the F4/80 marker of macrophages. (Right) Quantification of the F4/80 signal
in pellets n = 4; *P < 0.05.
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clones (G11, D11, B2, G2) after they had been allowed to form
tumors either s.c. (S-PT-U373 series) or in the mouse brain
(B-PT-U373 series). Upon short culture, these cells (S/B-PT-TF-
U373) were injected into SCID mice either s.c. (in Matrigel), or
intracranially and were followed over time using bioluminescence
imaging (Fig. 3A). Surprisingly, S-PT-TF-U373 cells did not re-
capitulate the latent growth pattern of their TF-U373 predecessors
but instead formed aggressive tumors shortly after inoculation. This
observation suggests that TF-related cessation of dormancy
results in a durable change in the cellular phenotype, an event
that likely occurs during latent periods of growth within the
procoagulant, inflammatory, and vascular microenvironment
provoked by TF expression.
To capture the molecular hallmarks of this transformation,
Matrigel pellets containing TF-U373 G11 cells and their isogenic
S-PT-TF-U373-G11 counterparts were recovered from the in-
jection site at day 16 (before any overt tumor formation), and the
human gene-expression profile was analyzed using the Affyme-
trix Human Genome Array U133 plus 2.0 platform (Fig. 3 B–D).
We observed altered expression of several genes, including 1,186
genes up-regulated by twofold or more and 133 genes down-
regulated to the same extent in S-PT-TF-U373-G11 inocula
versus controls (TF-U373-G11). A number of these changes also
were validated using semiquantitative RT-PCR. Once again, IPA
analysis revealed a consistent involvement of transcripts linked
to pathways such as Cancer, Inflammatory Response, and Cell
Cycle (Fig. 3 C and D and SI Appendix).
Notably, the S-PT-TF-U373 series of cell lines exhibited more
elongated morphology in vitro, along with a somewhat enhanced
growth potential and permanently altered expression of several
genes (RAP1A, UGT8, MGP, IFI6, and IFITM1). In conjunction
with the cells’ constitutively higher in vivo aggressiveness, these
observations suggest that, these cells may have undergone not
only a durable but, in fact, a permanent, genetic change during
the course of their initial latency. To examine this possibility, we
analyzed DNA copy number variation (CNV) using the Affy-
metrix SNP 6.0 platform to detect the possible genomic gains
and losses that would separate S-PT-TF-U373-G11 cells from
their isogenic TF-U373-G11 counterparts (Fig. 4A). Indeed, al-
though the genome of both cell lines was a priori highly abnor-
mal (as might be expected in the case of cancer cells), we did
observe that the respective cell lines differed in several genomic
regions, especially in chromosomes 2, 3, 5, 7, 12, and 22.
Lasting changes in cellular properties also may be driven by
the epigenome. An important hallmark of such changes is as-
sociated with aberrant DNA methylation, especially on cytosine
in CpG dinucleotides. To explore this possibility, we used the
reduced representation bisulfite sequencing (RRBS) method to
detect genome-wide differences in DNA methylation at CG-
dense regions that could separate TF transfectants and their
tumor-derived (S-PT) counterparts. This analysis was performed
on serially cultured cell lines in vitro and thus was outside the
immediate influence of the host-tissue microenvironment and
mouse cell contamination. Several independent, isogenic, TF-
transfected clones exhibited a consistent and similar methylation
pattern that was markedly different from that of their corre-
sponding S-PT variants (Fig. 4B). A range of differentially meth-
ylated sequences was found between the TF and S-PT cells.
Although loss of methylation was pronounced and widespread in
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Fig. 3. Growth in the TF-controlled microenvironment provokes permanent
changes in cellular phenotype. (A) Expression of a highly tumorigenic phe-
notype in TF-expressing glioma cells after their passage as tumors in SCID
mice. (Left) Bioluminescent images of s.c. primary tumors (S-PT-TF-U373-
G11); arrows indicate the time of tumor onset in various experiments (SI
Appendix). (Right) Line graph summarizing of tumor growth for all mice in
the group (n = 5). (B) Changes in the gene-expression profile between TF-
U373-G11 cells and their tumor-derived variant (S-PT-U373-G11). The heat-
map generated from the output of the human Affymetrix U133 array
compares the levels of 10 most different mRNA species between TF-U373-
G11 and S-PT-TF-U373-G11 cells embedded in Matrigel pellets in vivo (day 16
postinjection). (C) List of genes validated by semiquantitative RT-PCR. (D)
Table showing the top three networks according to the IPA software, in-
cluding genes with a greater than twofold change.
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Fig. 4. Growth of glioma cells in the TF-controlled microenvironment drives
permanent changes in cellular genome and epigenome. (A) CNV differences
between TF-U373-G11 cells and their derived isogenic variant S-PT-U373-G11
generated in vivo (see text). SNP analysis (Affymetrix 6.0) documents altered
regions of genomic DNA. (B) Cellular methylome profiling using the RRBS
strategy between indicated cell lines cultured in vitro. Hyper- and
hypomethylated tiles with a greater than 20% difference in methylation
between conditions and Fisher’s exact test (q-value <0.01) were used to
create the heatmap. There is a clear separation between the GpC methyla-
tion profiles of several independent TF-expressing clonal cell lines and their
tumor-derived counterparts (the PT series of cell lines).











S-PT variants, a portion of the affected sites were hypermethylated.
This discrepancy in methylation is consistent and commonly ob-
served in GBM and other tumor cells (36). The genomic regions
found to be altered in this setting included mainly introns (41%),
intergenic sequences (35%), and promoters (11%). The majority
of the differentially methylated sequences did not correspond to
regions where CNVs were found between the S-PT-TF-U373-G11
and TF-U373-G11 cells.
Overall, these observations suggest that microenvironmental
changes orchestrated by tumor cell-associated TF (procoagulant/
vascular responses) are capable of inducing permanent genetic
and epigenetic alterations in these cells as they progress to an
overtly tumorigenic phenotype.
Discussion
Dormancy is infrequently discussed in the context of GBM, in
part because long periods of remission are rare in this devas-
tating disease; instead, clinical demise is preceded by relatively
short median survival of ∼12–15 mo postdiagnosis despite stan-
dard care, including surgery and radio/chemotherapy (23). Some
variations may occur between clinically distinct molecular sub-
sets of the disease (37) and between patients with primary and
secondary pathways of GBM progression (38). Nonetheless, in
the great majority of adult GBM cases tumors are discovered de
novo (as primary GBM) and present as rapidly progressing,
highly invasive, intractable lesions, seemingly without evidence of
prior alterations or prolonged dormancy posttherapy.
However, we suggest that dormant behavior could be relevant
to the biology of GBM cells before overt disease onset and might
be subject to targetable changes in the tissue microenvironment.
For example, puzzling observations in the literature suggest that
clinically evident primary GBMs may emerge within 4–10 mo of
ostensibly negative brain imaging results (32). These tumors are
known to contain cells already endowed with a highly complex
repertoire of chromosomal losses, gains, amplifications, muta-
tions, and epigenetic changes involving several genes (e.g., EGFR,
PDGFR, PTEN, MDM2, Rb, p16/Ink4a, PI3K) (23). It is unlikely
that such aberrations could emerge during such a short period
(i.e., within months) and suggest that a more lengthy and cryptic
natural history could precede the diagnosis (39).
GBM also is reportedly more frequent in individuals who have
sustained head injury or experienced unexplained seizures (33,
40). These considerations raise the possibility, which warrants
study, of interactions between tissue repair processes in the brain
and premalignant or dormant tumor cells before clinical detection.
Such dormant disseminated cells also could exist at remote cranial
sites, where microenvironmental perturbations could affect re-
current growth. In this regard our results suggest the possibility
that activation of the coagulation system by changes in cellular
phenotype, hypoxia, or microinjury could set off a cascade of in-
flammatory and vascular events promoting the onset of malignant
lesion. Indeed, Karpatkin and colleagues previously suggested
a possible role of thrombin in cancer dormancy (41).
Tumor progression increasingly is linked to the presence of
local and bone marrow–derived CD11b+ cells and macrophages,
features that we observed before TF-driven “awakening” of
U373 glioma (42–45). Interestingly, cancers known to express
high levels of TF often possess proinflammatory stroma, as do
pancreatic (46) and colorectal cancers in which TF also may
regulate the onset of tumor progression (20).
Whether the recruitment of macrophages by TF-U373 cells
represents a true inflammatory response and the functional po-
larization of these infiltrating cells (M1/M2) remains to be de-
termined. Nonetheless, these TF-dependent microenvironmental
changes occur several weeks before the clinical manifestation of
tumor growth and are followed by secondary events including
phenotypic, genetic, and epigenetic alterations in cancer cells.
The mechanisms linking TF-driven changes in the microenvi-
ronment and alterations in the cancer cell genome and epi-
genome remain presently unknown, as are their key target genes.
It is possible that inflammatory cells recruited to the site of
chronic coagulation produce cellular stimulants (cytokines) and
mutagens (e.g., reactive oxygen species) (47) with genome-altering
consequences. Although carcinogenic effects of inflammation
have been widely discussed in the context of chronic infections
(48), our study suggests that the coagulation pathway also may be
a part of similar processes in cancer. Indeed, the incidence of
certain cancers is markedly elevated in patients with specific types
of coagulopathy, as exemplified by the increased frequency of co-
lon cancer in individuals with homozygous Factor V Leiden mu-
tation (19). How the coagulation system interacts with cancer and
dormant cells in different thrombophilias warrants further study.
The role of TF in the progression of various cancers is hardly
uniform. Thus, in several experimental studies TF obliteration was
shown to impede tumor growth (49–52), but other studies have
shown that TF-negative cells may readily form aggressive tumors
in mice (53–56). Similar differences could be expected also among
patients with brain tumors. GBM represents a molecularly het-
erogeneous group of diseases, including subtypes with distinctively
different profiles of tumor coagulome, only some of which include
high levels of TF (29). We posit that the control of tumor dor-
mancy by the coagulation/inflammation pathway also may be het-
erogeneous and potentially subtype specific. Indeed, high TF
levels tend to segregate with high levels of EGFR, especially in the
classical subtype of GBM. However, other GBM subtypes exhibit
other prominent alterations in the expression of coagulation-
related genes. It is possible that TF may play a different or lesser
role in tumor–vascular interactions in these diverse settings (29).
Although many questions still remain unanswered, our study
highlights the importance of the procoagulant microenvironment
in the control of tumor dormancy and suggests that the clotting
system may exert a hitherto unsuspected impact on genetic and
epigenetic alterations, tumor dormancy, and progression. We
propose that a better control of hemostatic perturbations may
offer new means of therapy, control, and prevention in cancers,
including, but possibly not restricted to, glioma.
Materials and Methods
Cell Lines, Culture Conditions, and Tumor Formation in Matrigel. All cell lines
were maintained under standard conditions unless otherwise indicated.
Matrigel (BD Biosciences) was mixed with 5 × 106 cells (of the cell line of
interest) and injected s.c. into SCID mice. All procedures involving animals
were performed in accordance with the guidelines of the Canadian Council
of Animal Care and the Animal Utilization Protocols approved by the In-
stitutional Animal Care Committee at McGill University Health Centre Research
Institute and McGill University. Tissues were collected for immunostaining as
detailed in SI Appendix.
Molecular Profiling. The platforms used for molecular profiling were Affy-
metrix 6.0 SNP Array, Affymetrix Human Genome U113 2.0 Array, and IPA
(Ingenuity Systems; www.ingenuity.com). Heatmaps were generated using
MeV software (57, 58). This profiling and reduced representation bisulfite
sequencing (RRBS) methylation assays are delineated in SI Appendix (59) and
were analyzed (60) as described earlier (61). Differentially methylated
sequences were annotated using HOMER version 3.51 (62).
Statistical Analysis. All experiments were reproduced at least twice with
similar results, or independently validated, and are presented as number of
replicates (n) and mean value of replicates ± SD. Statistical analyses were
performed using JMP 10.0 (SAS Institute, Inc.) as indicated. Differences were
considered statistically significant when P < 0.05. Wilcoxon and log-rank
testing were performed for all mouse experiments. For all other experi-
ments, statistical analysis was performed using one-tailed, unpaired t test.
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